A new at-home saliva test for prostate cancer could outperform current testing methods, a new study suggests. Researchers have developed a simple spit test, that can be performed at home and does not ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

The prostate health index (PHI) is a blood test that more accurately assesses the risk of prostate cancer than a traditional PSA test. The PHI combines three different PSA tests to create one risk ...

A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence, Swedish ...

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer is ...

The first reliable test of whether men are at a high risk of prostate cancer has been developed by British scientists. The breakthrough raises the prospect of millions being screened for the disease ...

A remarkable scientific advancement could transform how prostate cancer is detected in men around the world. Researchers have developed a groundbreaking urine test that offers significant advantages ...

Experts have developed a new saliva test which analyses genetic variants in a man's DNA. The simple test, which can be performed at home and does not require a visit to a doctor, appeared to perform ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, today announced the commercial launch of the ArteraAI Prostate Test (Post‑RP) for ...